Plant species in the family
Peganum harmala, commonly called wild rue, Syrian rue, African rue, esfand or espand, or harmel (among other similar pronunciations and spellings), is a perennial, herbaceous plant, with a woody underground rootstock, of the family Nitrariaceae, usually growing in saline soils in temperate desert and Mediterranean regions. Its common English-language name came about because of a resemblance to rue (to which it is not related). Its seeds contain a high concentration (at least 5.9% by weight) of diverse beta-carboline alkaloids.
It has deep roots and a strong smell, finely divided leaves, white flowers rich in alkaloids, and small seed capsules containing numerous dark, oily seeds. It is native to a vast region across North Africa, southern and eastern Europe, the Middle East, Central Asia, and parts of South and East Asia, and has been introduced to countries like South Africa, Mexico, France. It grows in dry, often saline or disturbed habitats, thriving from sea level to high elevations, is pollinated mainly by insects (especially honey bees), disperses seeds mostly by dispersal vectors or human activity, and hosts a specialized beetle (Thamnurgus pegani) proposed for its biological control.
Some scholars have associated it with the sacred plant called soma or haoma in ancient Indo-Iranian texts and it has been described under various names by classical and medieval sources, with archaeological evidence suggesting its ritual use dating back to at least the 2nd century BCE. It was first described and illustrated in the 16th century by Rembert Dodoens and later classified by botanists such as Gaspard Bauhin and Carl Linnaeus. It has several recognized varieties distinguished by morphological traits and geographic distribution, with lectotype designations refined over time to clarify its taxonomy.
In the United States, it is banned or regulated as a noxious weed in several states requiring eradication, while internationally, possession and sale of the plant or its psychoactive alkaloids are illegal or controlled in several countries, including France, Finland, Canada, and Australia. It is used as a dye, incense, and in traditional medicine. It is also toxic to livestock and difficult to eradicate.
Safety at a Glance
High Risk- Absolute contraindication in pregnancy. P. harmala is a documented abortifacient. Do not use if pregnant or potential...
- Have a sitter. The combined MAOI effect and potential for intense visionary experiences when combined with DMT source...
- Toxicity: Peganum harmala alkaloids have a meaningful toxicity profile that warrants serious respect. The LD50 of harmaline in ...
- Dangerous with: 1,4-Butanediol, 2-Aminoindane, 2-FA, 2-FEA (+123 more)
- Overdose risk: Limited specific overdose data is available for Peganum harmala. In the absence of compound-speci...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 3 hrs – 7 hrsHow It Feels
The onset of Peganum harmala — Syrian rue — begins within twenty to forty-five minutes with a distinctive physical signature. Nausea builds steadily, deep and purposeful, centered in the stomach and radiating outward. This nausea is not a side effect but a central feature of the experience, and for many, purging becomes the first significant event. The body feels increasingly heavy, and a warm, slightly sedating quality spreads through the limbs. There is a dizziness that intensifies with movement, making stillness the only comfortable option. The overall physical impression is one of the body being gradually subdued — activity and exertion become unappealing, and a reclined posture begins to feel not just comfortable but necessary.
As the harmala alkaloids — harmine, harmaline, tetrahydroharmine — saturate the monoamine oxidase enzymes and begin their work at serotonin receptors, the experience develops a contemplative, introspective quality. Colors warm slightly, taking on a golden or amber tone. With eyes closed, subtle geometric patterns may appear — not the vivid, complex architecture of DMT but gentle, flowing forms in earth tones that pulse slowly in rhythm with the breath. There is a dreamy quality to thought, a willingness to follow trains of reflection that would normally be dismissed as idle. Memories surface with unusual emotional clarity.
At peak, one to three hours in, the state is something between meditation and mild psychedelia. The emotional landscape opens — grief, tenderness, gratitude, and sorrow may move through in waves that feel both cathartic and manageable. The body remains heavy and still, and there is a deep, almost somatic sense of introspective gravity, as though the medicine is pulling the attention downward into the body's own emotional storage. The tremor that harmala alkaloids can produce — a fine, visible shaking in the hands — serves as a constant physical reminder of the pharmacological process underway.
The decline is gradual, two to three hours, and the aftermath is typically one of physical tiredness paired with emotional clarity. The nausea resolves. The tremor fades. What remains is often a quiet, clear-headed sense of having processed something — an emotional digestion that mirrors the physical one. Peganum harmala alone lacks the fireworks of full ayahuasca, but its practitioners argue that this quietness is the point: it offers a space for emotional work that does not require the overwhelming visionary intensity of DMT to be meaningful.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(7)
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Tremors— Involuntary rhythmic shaking of the hands, limbs, or body, ranging from fine tremor to gross shaking...
Cognitive & Perceptual Effects
Visual(1)
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Cognitive(2)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
Pharmacology
Peganum harmala seeds contain three principal beta-carboline alkaloids: harmine (3–4% of seed weight), harmaline (1–2%), and tetrahydroharmine (THH, trace amounts). Harmine and harmaline are reversible inhibitors of monoamine oxidase type A (MAO-A), with harmaline being somewhat more potent and faster-acting. They inhibit MAO-A competitively with IC50 values in the nanomolar range. Tetrahydroharmine preferentially inhibits serotonin reuptake (a weak SSRI) rather than acting primarily as an MAO inhibitor.
MAO-A normally degrades serotonin, norepinephrine, melatonin, and DMT (N,N-dimethyltryptamine). By inhibiting MAO-A, harmine and harmaline allow orally ingested DMT to reach the brain — the pharmacological basis of P. harmala as the MAOI component in "anahuasca" (pharmahuasca or synthetic ayahuasca), where it is combined with a DMT-containing plant or pure DMT.
At pharmacologically active doses (1–3 g of seeds, or 50–300 mg harmaline equivalent), the beta-carbolines themselves produce mild psychoactive effects: sedation, muscle tremors (harmaline specifically has tremorigenic properties), visual patterning, and anxiety or euphoria depending on dose and individual. These effects are distinct from and additive to any combined DMT experience.
Harmine crosses the blood-brain barrier and inhibits MAO-B more weakly than MAO-A, contributing to increased dopamine and phenylethylamine (PEA) in the brain. Harmine also inhibits glycogen synthase kinase-3 beta (GSK-3β), a kinase involved in neurogenesis and neuroprotection, which may underlie some of its antidepressant effects observed in rodent models.
Detection Methods
Urine Detection
Peganum harmala (Syrian rue) seeds contain beta-carboline alkaloids: harmine, harmaline, and harmalol. These are the same MAO-inhibiting compounds found in Banisteriopsis caapi (ayahuasca vine). They are not detected by standard immunoassay-based urine drug screens. The urine detection window is approximately 24 to 48 hours. Metabolites include harmol, harmalol, and their glucuronide conjugates.
Blood and Serum Detection
Blood detection windows for harmine and harmaline are approximately 4 to 16 hours. Both are rapidly metabolized by MAO and CYP enzymes. LC-MS/MS provides specific identification and quantification.
Standard Drug Panel Inclusion
Peganum harmala alkaloids are NOT included on any standard drug panel. They do not cross-react with any immunoassay target. Detection is relevant only in specific forensic or clinical toxicology contexts.
Confirmatory Methods
LC-MS/MS targeting harmine, harmaline, harmalol, and their metabolites provides definitive analysis. The same methods used for Banisteriopsis caapi detection apply.
Reagent Testing (Harm Reduction)
The Ehrlich reagent produces a purple to violet reaction with Syrian rue extracts due to the indole ring system of beta-carbolines. The Marquis reagent may produce variable reactions. Reagent testing confirms the presence of indole alkaloids. Seeds can be identified visually based on their distinctive appearance. Reagent testing cannot determine alkaloid potency, which varies significantly between seed batches.
Interactions
| Substance | Status | Note |
|---|---|---|
| 1,4-Butanediol | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| 2-Aminoindane | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 2-FA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 2-FEA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 2-FMA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 2,5-DMA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 2C-H | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 2M2B | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| 3-FA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 3-FEA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 3-FMA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 3-FPM | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 3-MMC | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 3,4-CTMP | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 4-FA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 4-FMA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 4-MMC | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 4F-EPH | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 4F-MPH | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 5-APB | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 5-MAPB | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| 5-MeO-MiPT | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| 6-APB | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| 6-APDB | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 8-Chlorotheophylline | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| A-PHP | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| A-PVP | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Acetylfentanyl | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Adrafinil | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Alcohol | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Alprazolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Amphetamine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Armodafinil | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Baclofen | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Benzodiazepines | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Benzydamine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Bromantane | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Buprenorphine | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Butylone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Caffeine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Cake | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Carisoprodol | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Clonazepam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Clonazolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Clonidine | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Cocaine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Codeine | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Cyclazodone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Deschloroetizolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Desomorphine | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Desoxypipradrol | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Dextroamphetamine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Dextropropoxyphene | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Diazepam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Dichloropane | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Diclazepam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Dihydrocodeine | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Ephedrine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Ephylone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Eszopiclone | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| ETH-CAT | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Ethylmorphine | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Ethylone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Ethylphenidate | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Etizolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| F-Phenibut | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Fenethylline | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Fentanyl | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Flualprazolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Flubromazepam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Flubromazolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Flunitrazepam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Flunitrazolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Gabapentin | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Gaboxadol | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| GBL | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| GHB | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Grayanotoxin | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Heroin | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Hexedrone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Hydrocodone | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Hydromorphone | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Isopropylphenidate | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Kratom | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Lisdexamfetamine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Lorazepam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| MCPP | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDAI | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| MDEA | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| MDMA | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDPV | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Mephenaqualone | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Methadone | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Methamphetamine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Methaqualone | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Methcathinone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Methiopropamine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Methylnaphthidate | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Methylone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Methylphenidate | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Metizolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Mexedrone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Midazolam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Mirtazapine | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Modafinil | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Morphine | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| N-Ethylhexedrone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| N-Methylbisfluoromodafinil | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Naloxone | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| NEP | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Nicotine | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Nifoxipam | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| NM-2-AI | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| O-Desmethyltramadol | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Oxiracetam | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Oxycodone | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Oxymorphone | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Pentedrone | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Pentobarbital | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Pethidine | Dangerous | Risk of serotonin syndrome and severe respiratory depression; potentially fatal |
| Phenobarbital | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Phenylpiracetam | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| PMA | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| PMMA | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| Rhodiola Rosea | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| SAMe | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| 1,3-Butanediol | Caution | MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution |
| 1B-LSD | Caution | MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution |
| 1cP-AL-LAD | Caution | MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution |
| 1cP-LSD | Caution | MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution |
| 1cP-MiPLA | Caution | MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution |
History
Peganum harmala has one of the richest ethnobotanical histories of any psychoactive plant, used across a vast geographic range from North Africa and the Middle East through Central Asia and into the Indian subcontinent for thousands of years.
The plant was likely the historical "haoma" of the ancient Persian Zoroastrian tradition and may be the same as the Vedic soma of ancient India — though this identification remains contested among scholars. Archaeological evidence from prehistoric burial sites in the Xinjiang region of China and in Iran supports ancient ceremonial use.
In the Middle East, P. harmala seeds (esfand or isfand) are burned as incense for protection against the "evil eye" — a practice still common in Iran, Afghanistan, and the broader region. The smoke from burning seeds contains harmaline and harmine vapors, which are bioactive through inhalation.
In traditional medicine, P. harmala has been used as an abortifacient, for wound healing, as an anthelmintic (anti-parasite), and for treating fever, malaria, lumbago, and numerous other conditions across North Africa, the Middle East, and Central Asia.
Western scientific interest in P. harmala alkaloids dates to the 1840s when harmaline was first isolated. Harmine was briefly known as "telepathine" in early 20th century literature due to mistaken identification with the active principle of ayahuasca, before it was recognized as the same compound.
Modern use as an ayahuasca analog MAOI component grew from the work of Jonathan Ott and others in the 1990s who systematically explored DMT-containing plant and alkaloid combinations. P. harmala seeds became widely available through online botanical vendors in the 2000s–2010s, making anahuasca preparation accessible to a much broader population than traditional ayahuasca ceremony.
Harm Reduction
Dose carefully and weigh your seeds. Alkaloid content varies between seed batches (harmaline 1–4% of seed weight). Weigh doses; do not eyeball. A standard MAOI dose for ayahuasca analogs is typically 1.5–3 g of seeds or 50–150 mg of extracted alkaloids. More is not better — excessive MAOI dosing increases tremor, nausea, and interaction risks without proportionally enhancing the combined experience.
Observe full MAOI precautions. Avoid all serotonergic substances (SSRIs, SNRIs, lithium, MDMA, tramadol, St. John's Wort) for at least 24 hours before and after use. Avoid tyramine-rich foods for 24 hours before use (aged cheeses, cured meats, fermented foods, beer, wine). Do not combine with any stimulants, cocaine, or opioids.
Absolute contraindication in pregnancy. P. harmala is a documented abortifacient. Do not use if pregnant or potentially pregnant.
Nausea management. Nausea is extremely common with P. harmala seeds. Light fasting (6+ hours) before use significantly reduces nausea. Ginger tea before ingestion may help. Many users find water extraction or cold-water alkaloid extraction reduces nausea compared to eating raw seeds.
Have a sitter. The combined MAOI effect and potential for intense visionary experiences when combined with DMT sources warrants a trusted sober sitter, particularly for inexperienced users.
Start low, go slow. Sensitivity to harmaline's tremorigenic effects varies substantially between individuals. First-time users should start at 50–75 mg harmaline equivalent.
Toxicity & Safety
Peganum harmala alkaloids have a meaningful toxicity profile that warrants serious respect. The LD50 of harmaline in rats is approximately 120–200 mg/kg (IP), indicating moderate toxicity at elevated doses. Human overdose cases have been documented, typically involving either deliberate ingestion of large quantities for abortifacient purposes (P. harmala has traditional use as an abortifacient) or miscalculated ayahuasca analog preparations.
MAOI drug interactions represent the greatest risk in practice. All the same interaction warnings applicable to pharmaceutical MAOIs apply: serotonin syndrome with serotonergic drugs (SSRIs, SNRIs, MDMA, tramadol), hypertensive crisis with tyramine-rich foods and sympathomimetic drugs (amphetamines, cocaine), and potentiation of numerous other medications. The MAOI effect can persist for several hours after ingestion.
Tremor and ataxia are characteristic of harmaline at higher doses. Severe harmaline intoxication presents with tremor, ataxia, nausea/vomiting, and tachycardia. Doses above 300–400 mg harmaline equivalent produce serious motor incapacitation.
Abortifacient risk. P. harmala has been used traditionally as an abortifacient and is absolutely contraindicated in pregnancy. The alkaloids can cause uterine contractions and fetal harm.
Hepatotoxicity has been reported with chronic or high-dose use, though data are limited to case reports.
The relatively narrow therapeutic-to-toxic window (compared to safer MAOI sources) makes dosing precision important — particularly when purchasing seeds or extracts of variable alkaloid content.
Overdose Information
Limited specific overdose data is available for Peganum harmala. In the absence of compound-specific information, general principles apply:
If someone exhibits signs of medical distress after using Peganum harmala — difficulty breathing, severe confusion, seizures, chest pain, extremely elevated temperature, or loss of consciousness — treat it as a medical emergency. Call emergency services and be forthcoming about what was consumed. Medical professionals follow confidentiality protocols and their priority is saving lives.
Prevention remains the best approach: use the minimum effective dose, avoid combining with other substances, and always have a sober person present who can recognize signs of distress and call for help.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of serotonin syndrome and severe respiratory depression; potentially fatal
Unpredictable potentiation of CNS depression; risk of respiratory failure
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Unpredictable potentiation of CNS depression; risk of respiratory failure
Tolerance
| Full | Develops with repeated use over 1 - 2 weeks |
| Half | 3 - 5 days |
| Zero | 7 - 14 days |
Cross-tolerances
Legal Status
In the United States, it is considered an invasive, noxious weed in the following states: Arizona (prohibited noxious weed), California (A listed noxious weed), Colorado (A listed noxious weed), Nevada (noxious weed), New Mexico (class B noxious weed), and Oregon (A designated weed, under quarantine). This may require land owners to exterminate infestations on their land or be fined, and allows access to government grants to buy herbicides to do so. It is illegal to sell plants of this species in the states listed above. Since 2005, with caveats, the cultivation, possession or sale of this species is also illegal in Louisiana.
Since 2005, the possession of the seeds, the plant itself, and the alkaloids harmine and harmaline, which it contains, is illegal in France. In Finland the plant is officially listed as a medicinal plant, which means one would require a doctors prescription to acquire it. In Canada, harmaline is illegal. In Australia, harmala alkaloids are illegal.
Experience Reports (2)
Tips (5)
Keep a usage log for Peganum harmala including dose, time, effects, and side effects. This helps you identify patterns and prevent problematic escalation.
The harmala alkaloids in Syrian rue are potent MAO inhibitors. You must follow tyramine dietary restrictions for at least 24 hours before and after use. This means no aged cheese, cured meats, fermented foods, or soy sauce. Serotonergic drugs including SSRIs and MDMA are potentially lethal combinations.
Peganum harmala (Syrian rue) has confirmed anticholinergic activity in addition to its MAOI effects. If you have developed sensitivity to anticholinergic substances from prior deliriant use, even standard doses of Syrian rue may trigger restless legs, dry mouth, and significant discomfort.
Research potential interactions before combining Peganum harmala with other substances. Drug interactions can be unpredictable and dangerous.
If you are sensitive to the anticholinergic effects of Syrian rue, B. caapi vine may be a more tolerable source of harmala alkaloids. The alkaloid profile differs somewhat and some users report fewer peripheral side effects, though the MAOI dietary restrictions still apply.
Community Discussions (1)
See Also
References (2)
- Peganum harmala - TripSit Factsheet
TripSit factsheet for Peganum harmala
tripsit - Peganum harmala - Wikipedia
Wikipedia article on Peganum harmala
wikipedia